A new drug put every single patient’s rectal cancer into remission in new trial
Doctors were astonished when a new drug called dostarlimab caused a complete remission of rectal cancer in every single patient in a new trial. Sponsored by GlaxoSmithKline, the trial was small, with only 18 patients, and needs to be replicated, but the initial results were “unheard-of.” The trial participants underwent...